VARIABLE TERM ACCELERATED SHARE REPURCHASE TRANSACTIONLetter Agreement • August 8th, 2008 • Amgen Inc • Biological products, (no disgnostic substances) • New York
This letter agreement (this “Confirmation”) confirms the terms and conditions of the variable term accelerated share repurchase transaction (the “Transaction”) entered into between Amgen Inc. (“Counterparty”) and Lehman Brothers OTC Derivatives Inc. (“Bank”), on the Trade Date specified below. This Confirmation constitutes a “Confirmation” under the Agreement specified below. This Confirmation is sent on behalf both Bank and Lehman Brothers Inc. (“Agent”). Bank is not a member of the Securities Investor Protection Corporation.
AMENDMENT NO. 1 TO AMENDMENT NO. 2 TO THE ENBREL® SUPPLY AGREEMENTEnbrel® Supply Agreement • August 8th, 2008 • Amgen Inc • Biological products, (no disgnostic substances)
This Amendment No. 1 to Amendment No. 2 to the ENBREL Supply Agreement (“Amendment No. 2.1”) is made this 23rd day of June, 2008 (the “Amendment No. 2.1 Effective Date”) by and among IMMUNEX CORPORATION, a corporation of the State of Washington, having its principal place of business at One Amgen Center Drive, Thousand Oaks, California, 91320, U.S.A., together with its Affiliates (“Immunex”), WYETH (formerly known as American Home Products Corporation), a corporation of the State of Delaware having its corporate headquarters at Five Giralda Farms, Madison, New Jersey 07940, U.S.A. and acting through its Wyeth Pharmaceuticals Division (“Wyeth”), and BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG, (formerly doing business as “Boehringer Ingelheim Pharma KG”) a German corporation having a place of business at Birkendorfer Straße 65, 88397 Biberach an der Riss, Federal Republic of Germany (“BIP”), and amends the Enbrel Supply Agreement effective as of November 5, 1998, by and among Immunex, Wye
